

**REMARKS**

In response to the Restriction Requirement, dated September 11, 2006, Applicants hereby elect without traverse Group VIII (Claim 5, drawn to a method of diagnosing or treating congenital disorders, which comprises using the polynucleotides of Group III) and the species of the polynucleotide of SEQ ID NO: 5 which encodes the polypeptide of SEQ ID NO: 6 (i.e., SEQ ID NOs: 5 and 6).

Applicants have amended claims 3 and 5 to only recite the appropriate elected, SEQ ID NO: (SEQ ID. NO: 6 in claim 3, and SEQ ID: 5 in claim 5) and have withdrawn claims 1, 2, 4 and 6 to 9.


Applicants reserve the right to file one or more divisional, continuation, or continuation-in-part applications directed to withdrawn or canceled subject matter disclosed in the application as originally filed.

**CONCLUSIONS**

It is respectfully submitted that all claims are now in condition for allowance, early notice of which would be appreciated. Should the Examiner disagree, Applicant respectfully requests a telephonic or in-person interview with the undersigned attorney to discuss any remaining issues and to expedite the eventual allowance of the claims.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any necessary fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17, which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310.

Respectfully submitted,



Date: October 24, 2006

Mark J. Sullivan

Reg. No. 54,478

**Customer No.: 009629**

**MORGAN, LEWIS & BOCKIUS LLP**

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Telephone: (202) 739-3000

Facsimile: (202) 739-3001